Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens

All NewsApril 24, 2025

Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong global demand.

Latest Ratings for EW

DateFirmActionFromTo Feb 2022UBSUpgradesNeutralBuy Jan 2022Morgan StanleyMaintainsOverweight Jan 2022Raymond JamesMaintainsOutperform

View More Analyst Ratings for EW

View the Latest Analyst Ratings

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent